Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emricasan in NASH Cirrhosis with Severe Portal Hypertension
2015-004473-32Phase 2Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cirrhosis due to nonalcoholic steatohepatitis and Portal Hypertension (PH) comparing Emricasan with Placebo (2 arms). Primary endpoint: Mean Change from Baseline at Week 25 in Hepatic Venous Pressure Gradient (HVPG). Started Aug 2016; status: completed.
02
Drugs
emricasan
03
Conditions
cirrhosis due to nonalcoholic steatohepatitisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2015-004473-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004473-32.